Transfusion and Haematology Today - Issue 4/2004
137
Is TEL/AML1 fusion gene appropriate marker for minimal residual disease monitoringin children with acute lymphoblastic leukaemia?
J. Madžo, K. Mužíková, E. Froňková, L. Šrámková, L. Zemanová, J. Zuna, J. Starý, J. Trka
143
Chronic lymphocytic leukemia: mutationalstatus of the immunoglobulin heavy chain gene is a significant prognostic marker
V. Kuhrová, H. Francová, D. Klimešová, J. Mayer
149
Immune-deficient mouse asa model for the study of leukaemias
M. Doubek, K. Řeháková, P. Scheer, J. Doubek, J. Mayer
154
Anagrelide in the treatment of essential thrombocythemia
R. Pytlík, E. Cmunt, Z. Kleibl, T. Kozák
161
Transfusion and Haematology Today
2004 Issue 4
Most read in this issue
- Is TEL/AML1 fusion gene appropriate marker for minimal residual disease monitoringin children with acute lymphoblastic leukaemia?
- Anagrelide in the treatment of essential thrombocythemia
- Chronic lymphocytic leukemia: mutationalstatus of the immunoglobulin heavy chain gene is a significant prognostic marker
- Immune-deficient mouse asa model for the study of leukaemias